Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2015 1
2018 1
2019 3
2020 1
2021 1
2022 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.
Diacon AH, Barry CE 3rd, Carlton A, Chen RY, Davies M, de Jager V, Fletcher K, Koh GCKW, Kontsevaya I, Heyckendorf J, Lange C, Reimann M, Penman SL, Scott R, Maher-Edwards G, Tiberi S, Vlasakakis G, Upton CM, Aguirre DB. Diacon AH, et al. Among authors: vlasakakis g. Nat Med. 2024 Mar;30(3):896-904. doi: 10.1038/s41591-024-02829-7. Epub 2024 Feb 16. Nat Med. 2024. PMID: 38365949 Free PMC article. Clinical Trial.
Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin.
Keutzer L, You H, Farnoud A, Nyberg J, Wicha SG, Maher-Edwards G, Vlasakakis G, Moghaddam GK, Svensson EM, Menden MP, Simonsson USH, On Behalf Of The Unite Tb Consortium. Keutzer L, et al. Among authors: vlasakakis g. Pharmaceutics. 2022 Jul 22;14(8):1530. doi: 10.3390/pharmaceutics14081530. Pharmaceutics. 2022. PMID: 35893785 Free PMC article.
First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug.
Pieren M, Abáigar Gutiérrez-Solana A, Antonijoan Arbós RM, Boyle GW, Davila M, Davy M, Gitzinger M, Husband L, Martínez-Martínez MS, Mazarro DO, Pefani E, Penman SL, Remuiñán MJ, Vlasakakis G, Zeitlinger M, Dale GE. Pieren M, et al. Among authors: vlasakakis g. J Antimicrob Chemother. 2024 Jun 3;79(6):1353-1361. doi: 10.1093/jac/dkae107. J Antimicrob Chemother. 2024. PMID: 38656557 Free PMC article. Clinical Trial.
Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo-controlled first-in-human study in healthy volunteers.
Fernando D, Dimelow R, Gorey C, Zhu X, Muya C, Parker C, Wright W, Soleman S, Walsh S, Crause M, Vlasakakis G, Guiney W, Robertson N, Bergeal M, Cui Y, Krug AW, Uings I. Fernando D, et al. Among authors: vlasakakis g. Br J Clin Pharmacol. 2022 Feb;88(2):865-870. doi: 10.1111/bcp.15010. Epub 2021 Aug 22. Br J Clin Pharmacol. 2022. PMID: 34327739 Free article. Clinical Trial.
Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin.
Johnson RC, Sáez-López E, Anagonou ES, Kpoton GG, Ayelo AG, Gnimavo RS, Mignanwande FZ, Houezo JG, Sopoh GE, Addo J, Orford L, Vlasakakis G, Biswas N, Calderon F, Della Pasqua O, Gine-March A, Herrador Z, Mendoza-Losana A, Díez G, Cruz I, Ramón-García S. Johnson RC, et al. Among authors: vlasakakis g. Trials. 2022 Jul 8;23(1):559. doi: 10.1186/s13063-022-06473-9. Trials. 2022. PMID: 35804454 Free PMC article.
Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patients.
Vlasakakis G, Napolitano A, Barnard R, Brown K, Bullman J, Inman D, Keymeulen B, Lanham D, Leirens Q, MacDonald A, Mezzalana E, Page K, Patel M, Savage CO, Zamuner S, van Maurik A. Vlasakakis G, et al. Br J Clin Pharmacol. 2019 Apr;85(4):704-714. doi: 10.1111/bcp.13842. Epub 2019 Feb 5. Br J Clin Pharmacol. 2019. PMID: 30566758 Free PMC article. Clinical Trial.
Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus.
Shaddinger BC, Soffer J, Vlasakakis G, Shabbout M, Weston C, Nino A. Shaddinger BC, et al. Among authors: vlasakakis g. Diabetes Res Clin Pract. 2019 Jun;152:125-134. doi: 10.1016/j.diabres.2019.04.018. Epub 2019 Apr 18. Diabetes Res Clin Pract. 2019. PMID: 31004676 Clinical Trial.
12 results